Ursheet Parikh, partner at Mayfield and investor in Mammoth Biosciences, traces the evolution of life sciences tech companies that led to the trend of startups focused on creating assets for large pharmaceutical companies to buy. He describes how Mammoth, in contrast, built a platform-based company from the start, guided by their mission to impact and save as many lives as possible.

Video clips from: Building Biotech to Last [Entire Talk]

4 minutes

A Built-to-Last Biotech Mindset

Watch now

3 minutes

Aligning with Investors

Watch now

3 minutes

Market Selection for Biotech Platforms

Watch now

3 minutes

Bioethics from the Beginning

Watch now

4 minutes

Creating a Culture of Accountability in Biotech

Watch now

Share Post